FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386814524> ?p ?o ?g. }

• W4386814524 endingPage "2334" @default.
• W4386814524 startingPage "2334" @default.
• W4386814524 abstract "Autologous cell therapy manufacturing timeframes constitute bottlenecks in clinical management pathways of severe burn patients. While effective temporary wound coverings exist for high-TBSA burns, any means to shorten the time-to-treatment with cytotherapeutic skin grafts could provide substantial therapeutic benefits. This study aimed to establish proofs-of-concept for a novel combinational cytotherapeutic construct (autologous/allogeneic DE-FE002-SK2 full dermo-epidermal graft) designed for significant cutaneous cell therapy manufacturing timeframe rationalization. Process development was based on several decades (four for autologous protocols, three for allogeneic protocols) of in-house clinical experience in cutaneous cytotherapies. Clinical grade dermal progenitor fibroblasts (standardized FE002-SK2 cell source) were used as off-the-freezer substrates in novel autologous/allogeneic dermo-epidermal bilayer sheets. Under vitamin C stimulation, FE002-SK2 primary progenitor fibroblasts rapidly produced robust allogeneic dermal templates, allowing patient keratinocyte attachment in co-culture. Notably, FE002-SK2 primary progenitor fibroblasts significantly outperformed patient fibroblasts for collagen deposition. An ex vivo de-epidermalized dermis model was used to demonstrate the efficient DE-FE002-SK2 construct bio-adhesion properties. Importantly, the presented DE-FE002-SK2 manufacturing process decreased clinical lot production timeframes from 6-8 weeks (standard autologous combined cytotherapies) to 2-3 weeks. Overall, these findings bear the potential to significantly optimize burn patient clinical pathways (for rapid wound closure and enhanced tissue healing quality) by combining extensively clinically proven cutaneous cell-based technologies." @default.
• W4386814524 created "2023-09-18" @default.
• W4386814524 creator A5000623893 @default.
• W4386814524 creator A5007930836 @default.
• W4386814524 creator A5008338069 @default.
• W4386814524 creator A5009943779 @default.
• W4386814524 creator A5019918200 @default.
• W4386814524 creator A5030226258 @default.
• W4386814524 creator A5032987278 @default.
• W4386814524 creator A5037215950 @default.
• W4386814524 creator A5040290370 @default.
• W4386814524 creator A5070898403 @default.
• W4386814524 date "2023-09-16" @default.
• W4386814524 modified "2023-10-17" @default.
• W4386814524 title "Cutaneous Cell Therapy Manufacturing Timeframe Rationalization: Allogeneic Off-the-Freezer Fibroblasts for Dermo-Epidermal Combined Preparations (DE-FE002-SK2) in Burn Care" @default.
• W4386814524 cites W1964147985 @default.
• W4386814524 cites W1971576298 @default.
• W4386814524 cites W1972634870 @default.
• W4386814524 cites W1978040580 @default.
• W4386814524 cites W1982771591 @default.
• W4386814524 cites W1995986494 @default.
• W4386814524 cites W1997115690 @default.
• W4386814524 cites W1998048927 @default.
• W4386814524 cites W2012046594 @default.
• W4386814524 cites W2018282431 @default.
• W4386814524 cites W2022560435 @default.
• W4386814524 cites W2024700555 @default.
• W4386814524 cites W2034199390 @default.
• W4386814524 cites W2036718385 @default.
• W4386814524 cites W2039015141 @default.
• W4386814524 cites W2042207484 @default.
• W4386814524 cites W2042629233 @default.
• W4386814524 cites W2048899843 @default.
• W4386814524 cites W2049043712 @default.
• W4386814524 cites W2051740824 @default.
• W4386814524 cites W2053701112 @default.
• W4386814524 cites W2054314179 @default.
• W4386814524 cites W2059363083 @default.
• W4386814524 cites W2067691626 @default.
• W4386814524 cites W2075237635 @default.
• W4386814524 cites W2075470906 @default.
• W4386814524 cites W2079002914 @default.
• W4386814524 cites W2081583807 @default.
• W4386814524 cites W2121162934 @default.
• W4386814524 cites W2124441143 @default.
• W4386814524 cites W2138563048 @default.
• W4386814524 cites W2148569033 @default.
• W4386814524 cites W2164379398 @default.
• W4386814524 cites W2236375555 @default.
• W4386814524 cites W2324899967 @default.
• W4386814524 cites W2340560164 @default.
• W4386814524 cites W2411193139 @default.
• W4386814524 cites W2514137348 @default.
• W4386814524 cites W2790344264 @default.
• W4386814524 cites W2792990356 @default.
• W4386814524 cites W2807006685 @default.
• W4386814524 cites W2810154468 @default.
• W4386814524 cites W2911604931 @default.
• W4386814524 cites W2937086352 @default.
• W4386814524 cites W2949357154 @default.
• W4386814524 cites W2966129488 @default.
• W4386814524 cites W3010035568 @default.
• W4386814524 cites W3036297231 @default.
• W4386814524 cites W3103567660 @default.
• W4386814524 cites W3112859835 @default.
• W4386814524 cites W3135061060 @default.
• W4386814524 cites W3135642215 @default.
• W4386814524 cites W3156279091 @default.
• W4386814524 cites W3161228643 @default.
• W4386814524 cites W3163395735 @default.
• W4386814524 cites W3166176345 @default.
• W4386814524 cites W4210871777 @default.
• W4386814524 cites W4285006811 @default.
• W4386814524 cites W4292528167 @default.
• W4386814524 cites W4313582474 @default.
• W4386814524 cites W4385442289 @default.
• W4386814524 doi "https://doi.org/10.3390/pharmaceutics15092334" @default.
• W4386814524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37765300" @default.
• W4386814524 hasPublicationYear "2023" @default.
• W4386814524 type Work @default.
• W4386814524 citedByCount "0" @default.
• W4386814524 crossrefType "journal-article" @default.
• W4386814524 hasAuthorship W4386814524A5000623893 @default.
• W4386814524 hasAuthorship W4386814524A5007930836 @default.
• W4386814524 hasAuthorship W4386814524A5008338069 @default.
• W4386814524 hasAuthorship W4386814524A5009943779 @default.
• W4386814524 hasAuthorship W4386814524A5019918200 @default.
• W4386814524 hasAuthorship W4386814524A5030226258 @default.
• W4386814524 hasAuthorship W4386814524A5032987278 @default.
• W4386814524 hasAuthorship W4386814524A5037215950 @default.
• W4386814524 hasAuthorship W4386814524A5040290370 @default.
• W4386814524 hasAuthorship W4386814524A5070898403 @default.
• W4386814524 hasBestOaLocation W43868145241 @default.
• W4386814524 hasConcept C10882517 @default.
• W4386814524 hasConcept C111472728 @default.
• W4386814524 hasConcept C138885662 @default.
• W4386814524 hasConcept C141071460 @default.
• W4386814524 hasConcept C142724271 @default.

• next